GlassScriptPhysician profile
Madhu M Katikineni
NPI 1235182163
$2,343.42
in general payments reported to CMS, 2019-2025
18 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $245 · 2021: $242 · 2022: $282 · 2023: $163 · 2024: $371 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $722.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $372.79 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $328.21 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $237.77 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $222.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.31 | 2019-2022 | |
| Corcept Therapeutics | $57.95 | 2020-2023 | Korlym |
| Echosens North America, INC. | $56.66 | 2025 | Fibroscan |
| Abbott Laboratories | $44.43 | 2021-2022 | |
| Cequr Corporation | $39.73 | 2023-2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $37.39 | 2023-2024 | |
| Globus Medical, INC. | $31.06 | 2025 | Senza |
| Digital Diagnostics INC. | $29.18 | 2020 | |
| Amarin Pharma, INC. | $20.89 | 2021 | |
| Amgen INC. | $18.05 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $15.23 | 2025 | |
| Sanofi Pasteur INC. | $12.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$516,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhu Katikineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.